Sonlicromanol is under clinical development by Khondrion and currently in Phase II for Mitochondrial Diseases. According to GlobalData, Phase II drugs for Mitochondrial Diseases have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sonlicromanol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sonlicromanol is under development for the treatment of subacute necrotizing encephalomyelopathy (Leigh Disease), mitochondrial myopathy such as MIDD (Maternally Inherited Diabetes and Deafness), MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), inherited mitochondrial diseases, mitochondrial diseases in children and other redox indications and for COVID-19 associated acute respiratory distress syndrome. The drug candidate is administered orally. It is a small molecule which acts by controlling the oxidative and redox pathologies responsible for defects in mitochondria. It was also under development for Parkinson's disease and Leber’s hereditary optic neuropathy (LHON) (Leber optic atrophy).
Khondrion is a biopharmaceutical company that focuses on the discovery and development of small molecule therapeutics to treat mitochondrial diseases. The company’s pipeline products include KH176, KH744, and KH183. Its KH176 is developed to target the mitochondrial dysfunction by acting on cell biological processes. Khondrion develops therapies for mitochondrial diseases such as Leigh disease, MELAS, Leber’s hereditary optic neuropathy and other respiratory chain or oxidative phosphorylation disorders. The company also performs in-house drug discovery program for the development of new therapies, biomarkers, diagnostic applications and new technologies in the field of mitochondrial diseases. Khondrion is headquartered in Nijmegen, the Netherlands.
For a complete picture of Sonlicromanol’s drug-specific PTSR and LoA scores, buy the report here.